Literature DB >> 9888154

MIB-1 (Ki-67) index and transforming growth factor-alpha (TGF alpha) immunoreactivity are significant prognostic predictors for meningiomas.

D W Hsu1, J T Efird, E T Hedley-Whyte.   

Abstract

Mitotic index > 6, proliferating cell nuclear antigen (PCNA) index > 5%, high tumour grade and absence of progesterone receptors (PR) are significant predictors for poor outcome in meningiomas. Since MIB-1 (Ki-67) is a more specific cell proliferation marker, and overexpression of TGF-alpha is also associated with tumour progression, we compared the prognostic significance of these factors with the other indices. Intracranial meningiomas from 21 men and 36 women (age 54.5 +/- 1.7, mean +/- SEM) were classified as 24 benign, 24 atypical and nine malignant. Twenty-one of the 57 tumours recurred (mean interval to recurrence was 57.3 +/- 13.1 months). The mean follow-up period for patients without tumour recurrence was 81.9 +/- 8.7 months. MIB-1 labelling index (LI) was expressed as percentage of labelled nuclei to total tumour nuclei counted in the most densely labelled areas. Analysis of variance revealed significant differences between tumour grades for MIB-1 labelling indices (0.75 +/- 0.21 for benign, 3.2 +/- 0.57 for atypical 6.04 +/- 1.48 for malignant; P < or = 0.0066), and between malignant and non-malignant meningiomas for TGF alpha staining scores (P < or = 0.029). MIB-1 LI also correlated with mitotic and PCNA indices (P < or = 0.0001), but not with age of the patients. Male patients had higher tumour MIB-1 LI than females (P < or = 0.0128). Univariate analysis indicated that MIB-1 LI > 3%, TGF alpha score > 4 (scoring scale 0-5), mitotic index > 6, and negative PR status were significant factors for worse outcome. Higher MIB-1 LI, TGF alpha score and mitotic index as continuous variables were also significant negative predictors. With multivariate analysis, both MIB-1 LI and TGF alpha score remained significant factors when paired with all other variables: TGF alpha or MIB-1 LI, respectively, mitosis, PCNA, tumour grade, PR status, age, sex, postoperative radiation therapy. We conclude that MIB-1 LI and TGF alpha score are important independent prognostic indicators for patients with meningiomas.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9888154     DOI: 10.1046/j.1365-2990.1998.00150.x

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  18 in total

1.  Recurrences of meningiomas: predictive value of pathological features and hormonal and growth factors.

Authors:  Francesco Maiuri; Marialaura Del Basso De Caro; Felice Esposito; Paolo Cappabianca; Viviana Strazzullo; Guido Pettinato; Enrico de Divitiis
Journal:  J Neurooncol       Date:  2007-01-17       Impact factor: 4.130

Review 2.  New prospects for management and treatment of inoperable and recurrent skull base meningiomas.

Authors:  Mahlon D Johnson; Burak Sade; Michael T Milano; Joung H Lee; Steven A Toms
Journal:  J Neurooncol       Date:  2007-07-12       Impact factor: 4.130

3.  Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.

Authors:  Andrew D Norden; Jeffrey J Raizer; Lauren E Abrey; Kathleen R Lamborn; Andrew B Lassman; Susan M Chang; W K Alfred Yung; Mark R Gilbert; Howard A Fine; Minesh Mehta; Lisa M Deangelis; Timothy F Cloughesy; H Ian Robins; Kenneth Aldape; Janet Dancey; Michael D Prados; Frank Lieberman; Patrick Y Wen
Journal:  J Neurooncol       Date:  2009-06-28       Impact factor: 4.130

4.  Hypoxia inducible factor-1 is involved in growth factor, glucocorticoid and hypoxia mediated regulation of vascular endothelial growth factor-A in human meningiomas.

Authors:  Y Wu; K Lucia; M Lange; D Kuhlen; G K Stalla; U Renner
Journal:  J Neurooncol       Date:  2014-07-01       Impact factor: 4.130

5.  Expression of TGFalpha in meningiomas.

Authors:  J Halper; C Jung; A Perry; H Suliman; M P Hill; B Scheithauer
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

6.  Proliferation potential of spinal meningiomas.

Authors:  Florian Roser; Makoto Nakamura; Mattia Bellinzona; Rainer Ritz; Helmut Ostertag; Marcos S Tatagiba
Journal:  Eur Spine J       Date:  2005-05-31       Impact factor: 3.134

7.  Osteopontin expression is a valuable marker for prediction of short-term recurrence in WHO grade I benign meningiomas.

Authors:  Kuan-Yin Tseng; Min-Huey Chung; Huey-Kang Sytwu; Horng-Mo Lee; Kuan-Yu Chen; Chen Chang; Chih-Kung Lin; Che-Hung Yen; Jia-Hong Chen; Gu-Jiun Lin; Hsin-I Ma; Yi-Shian Yeh; Da-Tong Ju; Ming-Ying Liu; Dueng-Yuan Hueng
Journal:  J Neurooncol       Date:  2010-04-29       Impact factor: 4.130

Review 8.  Medical management of meningiomas.

Authors:  Wendy J Sherman; Jeff J Raizer
Journal:  CNS Oncol       Date:  2013-03

9.  Childhood and juvenile meningiomas.

Authors:  Xing Gao; Rong Zhang; Ying Mao; Yin Wang
Journal:  Childs Nerv Syst       Date:  2009-07-30       Impact factor: 1.475

10.  Early recurrences in histologically benign/grade I meningiomas are associated with large tumors and coexistence of monosomy 14 and del(1p36) in the ancestral tumor cell clone.

Authors:  Angel Maillo; Alberto Orfao; Ana B Espinosa; José María Sayagués; Marta Merino; Pablo Sousa; Monica Lara; María Dolores Tabernero
Journal:  Neuro Oncol       Date:  2007-08-17       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.